Sanofi India Shareholders Approve Deepak Arora as Managing Director with 94.70% Votes

Sanofi India Limited has successfully completed the shareholder approval process for Deepak Arora's appointment as Managing Director, with the postal ballot concluding on December 17, 2025. The voting results demonstrate strong shareholder confidence in the new leadership appointment.

Shareholder Approval Results

The postal ballot voting, conducted through remote e-voting from November 18 to December 17, 2025, yielded decisive results for both resolutions. The scrutinizer's report, prepared by Gaurav Sainani of SGGS Associates, confirmed the approval of Deepak Arora's dual appointment.

Resolution:	Votes in Favour	Votes Against	Approval Rate
Director Appointment:	1,99,46,099	31,256	99.84%
Managing Director Appointment:	1,89,18,505	10,58,858	94.70%

Voting Process and Compliance

The postal ballot process was conducted in full compliance with Regulation 44 of SEBI Listing Regulations and the Companies Act, 2013. The cut-off date for eligible voters was November 14, 2025, and the notice was dispatched to shareholders via email on November 17, 2025.

New Leadership at the Helm

Deepak Arora's appointment as Managing Director, effective from October 27, 2025, brings over three decades of pharmaceutical and healthcare experience to Sanofi India. His career spans across various geographies including North America, Europe, Middle East, and Africa, where he has held leadership positions in commercial, sales, marketing, and general management roles.

Key Responsibilities and Strategic Vision

In his new position, Arora will be tasked with defining and driving the strategic vision for Sanofi in India, spearheading strategic priorities to boost innovation and agility, fostering operational excellence across all functions, and championing the company's Diversity, Equity, and Inclusion culture.

Management Transition Details

Rachid Ayari stepped down from his position as Interim Managing Director on October 26, 2025, after serving in the interim role since July 21, 2025. Ayari continues to serve as Whole-time Director and Chief Financial Officer of Sanofi India. The Board has also authorized Deepak Arora to determine the materiality of events and make stock exchange disclosures, alongside other Key Managerial Personnel.

This management change, now formally approved by shareholders, marks a new chapter for Sanofi India as it continues its mission to promote health and chase the miracles of science to improve people's lives across the entire health spectrum in India.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.23%	-1.87%	-6.43%	-31.65%	-33.38%	-48.28%

Sanofi India Limited (SIL), a prominent player in the pharmaceutical industry, has announced significant changes in its leadership team, specifically in the role of Company Secretary and Compliance Officer.

Resignation of Arjun Thakkar

Mr. Arjun Thakkar, the current Company Secretary and Compliance Officer of Sanofi India Limited, has tendered his resignation effective September 30, 2025. Thakkar's decision to step down comes as he pursues a new career opportunity within the Sanofi Group, specifically in the Ethics & Business Integrity department.

The company has expressed its appreciation for Thakkar's contributions during his tenure. With his departure, Thakkar will also cease to be a Key Managerial Personnel and Senior Management Personnel of the company.

Appointment of Haresh Vala

In light of this transition, the Board of Directors of Sanofi India Limited, upon recommendation from the Nomination and Remuneration Committee, has approved the appointment of Mr. Haresh Vala as the new Company Secretary and Compliance Officer. Vala's appointment will be effective from October 1, 2025.

About Haresh Vala

Mr. Haresh Vala brings a wealth of experience to his new role at Sanofi India Limited:

Professional Qualifications: Associate Member of the Institute of Company Secretaries of India
Experience: Over two decades in corporate secretarial and compliance functions across diverse industries
Education: Holds degrees in Law and Commerce from the University of Mumbai
Expertise: Deep knowledge in corporate governance, regulatory compliance, investor relations, SEBI regulations, and Companies Act compliances
Key Skills: Experienced in entity formation, capital structuring, fund-raising, dividend distribution, related party transactions, and compliance with LODR regulations

Vala's appointment is expected to strengthen Sanofi India's corporate governance framework and ensure compliance with regulatory requirements.

Additional Responsibilities

The Board has also authorized Mr. Haresh Vala to determine the materiality of events or information and make disclosures to the Stock Exchanges, in addition to other authorized Key Managerial Personnel. This responsibility is in line with Regulation 30(5) of the SEBI Listing Regulations.

Board Meeting Details

The decision regarding these leadership changes was made during a Board of Directors meeting held on September 25, 2025. The meeting commenced at 4:15 p.m. and concluded at 4:45 p.m.

These leadership changes at Sanofi India Limited reflect the company's commitment to maintaining strong corporate governance and ensuring smooth transitions in key roles. As the pharmaceutical industry continues to evolve, such strategic appointments are crucial for navigating regulatory landscapes and driving organizational growth.